

# Elecsys CMV IgG Avidity

cobas®

REF



SYSTEM

05909708 119

100; equals to 50 CMV IgG avidity determinations

MODULAR ANALYTICS E170

cobas e 411

cobas e 601

cobas e 602

## English

### System information

For **cobas e 411** analyzer: test number 640

For MODULAR ANALYTICS E170, **cobas e 601** and **cobas e 602** analyzers: Application Code Number 030

### Intended use

Immunoassay for the in vitro qualitative determination of the avidity of IgG antibodies to cytomegalovirus in human serum and plasma.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and **cobas e** immunoassay analyzers.

Note: Please note that the catalogue number appearing on the package insert retains only the first 8 digits of the licensed 11-digit Catalogue Number: 05909708190 for the CMV IgG Avidity assay. The last 3 digits -190 have been replaced by -119 for logistic purposes.

### Summary

Cytomegalovirus (CMV), a member of the herpes virus family, is ubiquitous in all human populations, causing infections which are followed by life-long latency in the host with occasional reactivations.<sup>1,2</sup> The seroprevalence of antibodies in adults ranges from 40-100 % with inverse correlation to socioeconomic status.<sup>1,2,3</sup> CMV is transmitted through body fluids, including blood, genital secretions and breast milk. Saliva and urine of infected individuals also represent a prominent source of infection, and children, especially those attending day care facilities, are an important vector for viral spread.<sup>2,3,4,5,6</sup> In immunocompetent individuals primary CMV infection is usually mild or asymptomatic.<sup>2,5</sup> Patients commonly present with a mononucleosis-like syndrome, including fever, sore throat, cervical lymphadenopathy, malaise, headache, muscle ache and joint pains.<sup>2,3,4,5,7</sup>

During pregnancy, CMV can cause congenital infection which may result in permanent physical and/or neurological sequelae in the child.<sup>5</sup> CMV infection can be primary, i.e. newly acquired, or secondary, i.e. due to reactivation of the latent virus or re-infection with a different viral strain.<sup>3,5</sup> Primary CMV infection is reported in 1-4 % of seronegative women during pregnancy and the risk of transmission to the fetus is estimated to be about 30-40 %.<sup>3,4</sup> Reactivation of CMV infection during pregnancy is reported in 10-30 % of seropositive women and, in this circumstance, the risk of transmission of the virus is about 1-3 %.<sup>3,4,5</sup> Overall, prenatal CMV infection occurs in 0.6-0.7 % of all life births in the developed world.<sup>4,5,8</sup> The majority of babies born with congenital CMV infection are asymptomatic at birth.<sup>8,9,10</sup> Of these 5-15 % still develop irreversible impairments, most frequently hearing loss, that can occur several months or even years after birth.<sup>5,8,9,10</sup> For babies symptomatic at birth, prognosis is very poor, as they are likely to develop severe mental impairment and/or hearing loss.<sup>5,8,9,10</sup> Different studies have shown that the risk of symptomatic congenital disease in the fetus or newborn infant is high, when maternal primary infection takes place in early pregnancy before week 20 of gestation, and lower thereafter.<sup>4,5</sup> The congenital CMV infection caused by recurrent maternal infection seldom leads to symptomatic disease at birth.<sup>4,5</sup>

At risk for CMV infection and disease are also immunocompromised patients such as transplant recipients and HIV infected patients where the virus can cause life-threatening diseases.<sup>11,12</sup> The CMV status of transplant donors and recipients is very important, as it will determine prophylactic and pre-emptive treatment strategies against CMV. CMV-negative transplant recipients should receive donations from CMV-negative individuals or leukocyte depleted blood products. During latency, CMV resides in infected cells and the free viral DNA load is usually low. The CMV status can still be determined by testing for CMV IgG antibodies.

Within the appropriate clinical context, the first step in diagnosing acute primary CMV infection is most commonly made by the detection of anti-CMV-specific IgG and IgM antibodies.<sup>5</sup> Samples being reactive for IgM antibodies indicate an acute, recent or reactivated infection.<sup>2,4,5,12</sup> For further analysis of a primary CMV infection the determination of the CMV IgG avidity is used as an aid.<sup>2,4,5,12</sup> The CMV IgG avidity assay measures the functional binding affinity of CMV IgG antibodies in response to infection. The antibodies produced during the primary response have lower antigen avidity than the antibodies produced later on.<sup>2,5,10</sup> Low avidity is encountered approximately up to 18-20 weeks after onset of symptoms in immunocompetent subjects.<sup>5,10</sup> However, individual variation does exist in the rate of avidity maturation. In rare cases low avidity results can be

observed up to 6 months or even longer after the onset of infection. The avidity testing should be performed early in gestation. Low avidity CMV IgG antibodies detected before the 16<sup>th</sup>-18<sup>th</sup> week of pregnancy in combination with positive CMV IgM result is a strong evidence for recent primary infection.<sup>3,5,10</sup> A high avidity result later after gestation (after 20<sup>th</sup> week of gestation) cannot rule out a primary infection earlier in gestation when low avidity CMV IgG may have been present.<sup>3</sup> A high avidity index during the first 12-16 weeks of pregnancy can be considered indicative of past infection.<sup>3,5,7,10</sup>

### Test principle

The test principle is based on two, parallel measurements with the Elecsys CMV IgG Avidity assay.

The first measurement is a reference measurement of the samples with the Elecsys CMV IgG Avidity assay. The second measurement is the DiICMVAv treated measurement of the samples using the automated sample specific dilution function of the analyzer with the avidity diluent (DiICMVAv) followed by the Elecsys CMV IgG Avidity assay. The avidity diluent contains components which interfere with the binding of low avidity CMV IgG antibodies.

The avidity (Avi%) is assessed by determining the ratio between the reference measurement and the DiICMVAv treated measurement.

The Elecsys CMV IgG Avidity assay uses the sandwich principle. Total duration of assay is 18 minutes for both reference measurement and DiICMVAv treated measurement.

- 1st incubation: 20 µL of sample (automatically diluted with DiICMVAv or undiluted reference), biotinylated recombinant CMV-specific antigens, and CMV-specific recombinant antigens labeled with a ruthenium complex<sup>a)</sup> form a sandwich complex. In case of the DiICMVAv treated measurement, only high avidity CMV antibodies are able to build up the sandwich complex, while the complex with low avidity CMV antibodies is dissolved.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent barcode or e-barcode.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)<sub>3</sub><sup>2+</sup>)

### Reagents - working solutions

The reagent rackpack (M, R1, R2) is labeled as CMV-AV.

- M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL:  
Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 CMV-Ag-biotin (gray cap), 1 bottle, 9 mL:  
Biotinylated CMV-specific antigen (recombinant, E. coli), > 400 µg/L, MES buffer 50 mmol/L, pH 6.5; preservative.
- R2 CMV-Ag-Ru(bpy)<sub>3</sub><sup>2+</sup> (black cap), 1 bottle, 9 mL:  
CMV-specific antigen (recombinant, E. coli) labeled with ruthenium complex > 400 µg/L; MES buffer 50 mmol/L, pH 6.5; preservative.

CMV-AV Cal1 Negative calibrator 1 (white cap), 2 bottles of 1.0 mL each:  
Human serum, non-reactive for anti-CMV IgG; buffer; preservative.

# Elecsys CMV IgG Avidity



CMV-AV Cal2 Positive calibrator 2 (black cap), 2 bottles of 1.0 mL each:  
Human serum, reactive for anti-CMV IgG, approx. 40 U/mL;  
buffer; preservative.

DilCMVAv Avidity Diluent (white cap), 1 bottle, 2.5 mL:  
0.8 M Guanidine chloride, CMV-specific antigen  
(recombinant, E. coli); MES-buffer 50 mmol/L, pH 6.5;  
preservative.

## Precautions and warnings

For in vitro diagnostic use.  
Exercise the normal precautions required for handling all laboratory reagents.  
Disposal of all waste material should be in accordance with local guidelines.  
Safety data sheet available for professional user on request.  
All human material should be considered potentially infectious.  
Both calibrators (CMV-AV Cal1, CMV-AV Cal2) have been prepared exclusively from the blood of donors tested individually and shown to be free from HBsAg and antibodies to HCV and HIV.  
The serum containing anti-CMV IgG (CMV-AV Cal2) was sterile filtered.  
The testing methods used assays approved by the FDA or cleared in compliance with the European Directive 98/79/EC, Annex II, List A.  
However, as no testing method can rule out the potential risk of infection with absolute certainty, the material should be handled with the same level of care as a patient specimen. In the event of exposure, the directives of the responsible health authorities should be followed.<sup>13,14</sup>  
Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

## Reagent handling

The reagents in the kit are ready for use and are supplied in bottles compatible with the system.  
**cobas e 411** analyzer: The calibrators should only be left on the analyzer during calibration at 20-25 °C. After use, close the bottles as soon as possible and store upright at 2-8 °C.  
Due to possible evaporation effects, not more than 5 calibration procedures per bottle set should be performed.  
MODULAR ANALYTICS E170, **cobas e 601** and **cobas e 602** analyzers: Unless the entire volume is necessary for calibration on the analyzer, transfer aliquots of the ready-for-use calibrators into empty snap-cap bottles (CalSet Vials). Attach the supplied labels to these additional bottles. Store the aliquots at 2-8 °C for later use.  
Perform **only one** calibration procedure per aliquot.

All information required for correct operation is read in from the respective reagent barcodes.

**Please note:** Both the vial labels, and the additional labels (if available) contain 2 different barcodes. The barcode between the yellow markers is for **cobas 8000** systems only. If using a **cobas 8000** system, please turn the vial cap 180° into the correct position so the barcode can be read by the system. Place the vial on the instrument as usual.

## Storage and stability

Store at 2-8 °C.  
Do not freeze.  
Store the Elecsys reagent kit and DilCMVAv **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability of the reagent rackpack and DilCMVAv	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	12 weeks
on the analyzers	3 weeks or 8 weeks if stored alternately in the refrigerator and on the analyzers (up to 8 hours at 20-25 °C)

Stability of the calibrators	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	8 weeks
on <b>cobas e 411</b> at 20-25 °C	up to 5 hours
on MODULAR ANALYTICS E170, <b>cobas e 601</b> and <b>cobas e 602</b> at 20-25 °C	use only once

Store calibrators **upright** in order to prevent the calibrator solution from adhering to the snap-cap.

## Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.  
Serum collected using standard sampling tubes or tubes containing separating gel.  
Li-heparin, K<sub>2</sub>-EDTA and K<sub>3</sub>-EDTA plasma.  
Criterion: Mean recovery of positive samples within 80-120 % of serum value.  
Stable for 4 weeks at 2-8 °C, 7 days at 25 °C, 6 months at -20 °C (± 5 °C).  
The samples may be frozen 5 times.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Specimens should not be subsequently altered with additives (biocides, anti-oxidants or substances that could possibly change the pH of the sample) in order to avoid erroneous findings.

Pooled samples and other artificial material may have different effects on different assays and thus may lead to discrepant findings.

Centrifuge samples containing precipitates and thawed samples before performing the assay. Lyophilized samples and heat-inactivated samples can be used.

Ensure the samples, calibrators and controls are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples, calibrators and controls on the analyzers should be analyzed/measured within 2 hours.

## Materials provided

See "Reagents – working solutions" section for reagents.

## Materials required (but not provided)

- [REF] 05942322190, PreciControl CMV IgG Avidity, 6 x 1.0 mL
  - [REF] 11732277122, Diluent Universal, 2 x 16 mL sample diluent or [REF] 03183971122, Diluent Universal, 2 x 36 mL sample diluent
  - [REF] 11776576322, CalSet Vials, 2 x 56 empty snap-cap bottles
  - General laboratory equipment
  - MODULAR ANALYTICS E170 or **cobas e** analyzer
- Accessories for **cobas e 411** analyzer:
- [REF] 11662988122, ProCell, 6 x 380 mL system buffer
  - [REF] 11662970122, CleanCell, 6 x 380 mL measuring cell cleaning solution
  - [REF] 11930346122, Elecsys SysWash, 1 x 500 mL washwater additive
  - [REF] 11933159001, Adapter for SysClean
  - [REF] 11706802001, AssayCup, 60 x 60 reaction cups
  - [REF] 11706799001, AssayTip, 30 x 120 pipette tips
  - [REF] 11800507001, Clean-Liner
- Accessories for MODULAR ANALYTICS E170, **cobas e 601** and **cobas e 602** analyzers:
- [REF] 04880340190, ProCell M, 2 x 2 L system buffer
  - [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution

# Elecsys CMV IgG Avidity



- [REF] 03023141001, PC/CC-Cups, 12 cups to prewarm ProCell M and CleanCell M before use
  - [REF] 03005712190, ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change
  - [REF] 12102137001, AssayTip/AssayCup, 48 magazines x 84 reaction cups or pipette tips, waste bags
  - [REF] 03023150001, WasteLiner, waste bags
  - [REF] 03027651001, SysClean Adapter M
- Accessories for all analyzers:
- [REF] 11298500316, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

## Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use. Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the 15-digit sequence of numbers (except for the **cobas e 602** analyzer).

Bring the cooled reagents to approximately 20 °C and place on the reagent disk (20 °C) of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the bottles.



Place the calibrators in the sample zone.

All the information necessary for calibrating the assay is automatically read into the analyzer.

After calibration has been performed, store the calibrators at 2-8 °C or discard (MODULAR ANALYTICS E170, **cobas e 601** and **cobas e 602** analyzers).

Each sample and the controls must be ordered twice (reference measurement and DiICMVAv treated measurement) to calculate the avidity (Avi%).

## Handling of specimen for the Elecsys CMV IgG Avidity assay



Samples found to be reactive in the Elecsys CMV IgG assay with concentrations between 1-500 U/mL are split up into two aliquots. If a sample is reactive in the Elecsys CMV IgG assay with a concentration > 500 U/mL, the sample has to be prediluted manually 1:20 with Diluent Universal (refer to the "Dilution" section) and then split up into two aliquots.

- **Reference measurement:**  
Place first aliquot of a given sample on the analyzer in position n and order a CMV IgG avidity measurement.
- **DiICMVAv treated measurement:**  
Place second aliquot of the above mentioned sample on the analyzer in position n+1 and order a CMV IgG avidity measurement with a "sample specific dilution" of 1:2. For further details please refer to the analyzer operator's manual. By means of this, the analyzer will mix 50 µL DiICMVAv with 50 µL sample prior to the CMV IgG avidity measurement.

Operator must ensure that both measurements are performed consecutively with the same reagent lot, with the same analyzer and the same calibration.

*Note:* If aliquoting of a sample is not possible, the two measurements have to be programmed and performed consecutively. Parallel, automated measurement of reference measurement and the DiICMVAv treated measurement from one aliquot is not possible.

## Calibration

**Traceability:** This method has been standardized against the internal Roche standard for CMV IgG. No international standard is available for CMV.

Every Elecsys CMV IgG Avidity reagent set has a barcoded label containing specific information for calibration of the particular reagent lot. The predefined master curve is adapted to the analyzer using CMV-AV Cal1 and CMV-AV Cal2.

**Calibration frequency:** Calibration must be performed once per reagent lot using CMV-AV Cal1, CMV-AV Cal2 and fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer).

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Renewed calibration is recommended as follows:

- after 1 month (28 days) when using the same reagent lot
- after 7 days (when using the same reagent kit on the analyzer)
- as required: e.g. quality control findings with PreciControl CMV IgG Avidity outside the defined limits
- more frequently when this is required by pertinent regulations

## Quality control

For quality control, use PreciControl CMV IgG Avidity.

It is recommended to run PreciControl CMV IgG Avidity 1 and 2 at the beginning of each working day and after every calibration. Prepare two aliquots of each control level. Place both aliquots of each control level one after another on a sample rack. Both levels must be run in parallel in the reference and in the DiICMVAv treated measurement as a performance check.

Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

# Elecsys CMV IgG Avidity



▪ Verification of the calibration:

The target values and ranges (U/mL) of the reference measurement were determined and evaluated by Roche. They were obtained using the Elecsys CMV IgG Avidity test reagents and analyzers available at the time of testing. The reference measurements of the controls have to be recovered within the control ranges (U/mL) as stated in the value sheet. The control values have to be compared manually to the CMV IgG ranges (U/mL) given in the value sheet. The exact lot-specific target values and ranges are printed on the enclosed (or electronically available) value sheet.

▪ Verification of the functionality of the Diluent Avidity (DiICMVAv):

The avidity (Avi%) is calculated from the reference measurement and the DiICMVAv treated measurement according to the "Calculation" section. The target range for the manually calculated avidity result (Avi%) of PreciControl CMV IgG Avidity 1 is < 45.0 Avi%, while the respective range for PreciControl CMV IgG Avidity 2 is ≥ 55.0 Avi%.

Note: The controls are not barcode-labeled and have to be treated as patient samples.

Controls must not be defined as external controls, as dilution of controls is not possible on the instrument.

**Calculation**

The analyzer automatically calculates the analyte concentration of each sample in U/mL for both measurements (reference measurement and DiICMVAv treated measurement). The avidity (Avi%) must be calculated manually:

$$Avi\% = \frac{\text{result DiICMVAv treated measurement}}{\text{result reference measurement}} \times 100\%$$

Only samples being reactive in the reference measurement (≥ 1.0 U/mL) can be used for the determination of avidity (Avi%).

If the DiICMVAv treated measurement results in values < 0.3 U/mL, please calculate avidity (Avi%) with 0.3 U/mL.

**Interpretation of the results**

Results obtained with the Elecsys CMV IgG Avidity assay are interpreted as follows:

Avidity	Interpretation
< 45.0 Avi%	low avidity
45.0-54.9 Avi%	gray-zone
≥ 55.0 Avi%	high avidity

No clinical interpretation can be deduced from a gray-zone result. It is recommended to take a follow-up sample within an appropriate period of time (e.g. 2-4 weeks) and repeat testing.

Elecsys CMV IgG Avidity results should be used in conjunction with the patient's medical history, clinical symptoms and other laboratory tests, e.g. CMV-specific IgG and IgM results.

In case of a CMV IgG avidity result discordant to the patient's medical history, clinical symptoms and other laboratory tests, e.g. CMV-specific IgG and IgM results, further tests should be performed to verify the result and testing of a follow up sample is recommended.

The CMV IgG avidity results in a given specimen, as determined by assays from different manufacturers, can vary due to differences in assay methods and reagents used. Therefore, the results reported by the laboratory to the physician should include: "The following results were obtained with the Elecsys CMV IgG Avidity assay. Results from assays of other manufacturers cannot be used interchangeably."

Avidity results up to 110 Avi% can occur due to the assay inherent variance and are interpreted as high avidity results. For avidity > 110 Avi%, it is advised to predilute (according to the "Dilution" section) the sample and repeat both measurements to calculate a new avidity (Avi%).

**Limitations - interference**

The results in HIV patients, in patients undergoing immunosuppressive therapy, or in patients with other disorders leading to immune suppression, should be interpreted with caution.

Specimens from neonates, cord blood, pretransplant patients or body fluids other than serum and plasma, such as urine, saliva or amniotic fluid have not been tested.

Among a panel of 142 positive samples within the measuring range no high-dose hook effect was observed (no increasing signals upon dilution). However, the occurrence of a high-dose hook effect cannot be excluded in other cohorts.

The assay is unaffected by icterus (bilirubin < 1129 µmol/L or < 66 mg/dL), hemolysis (Hb < 0.310 mmol/L or < 0.500 g/dL), lipemia (Intralipid < 2000 mg/dL) and biotin (< 246 nmol/L or < 60 ng/mL).

Criterion: Mean recovery of positive samples within ± 20 % of serum value.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

No interference was observed from rheumatoid factors up to a concentration of 1500 IU/mL.

In vitro tests were performed on 18 commonly used pharmaceuticals and in addition on ganciclovir and valganciclovir. No interference with the assay was found.

In rare cases, interference due to extremely high titers of antibodies to streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

**Limits and ranges**

**Measuring range**

• Reference measurement:

0.25-500 U/mL (defined by the Limit of Detection and the maximum of the master curve). Values below the Limit of Blank are reported as < 0.15 U/mL. Values above the Limit of Blank but below the Limit of Detection will not be flagged by the instrument. Values above the measuring range are reported as > 500 U/mL.

*Limit of Blank and Limit of Detection*

Limit of Blank = 0.15 U/mL

Limit of Detection = 0.25 U/mL

The Limit of Blank and Limit of Detection were determined in accordance with CLSI (Clinical and Laboratory Standards Institute) EP17-A requirements.

The Limit of Blank is the 95<sup>th</sup> percentile value from n ≥ 60 measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

• DiICMVAv treated measurement:

Due to the 1:2 dilution measuring range is 0.50-1000 U/mL. Values below the Limit of Blank are reported as < 0.30 U/mL. Values above the Limit of Blank but below the Limit of Detection will not be flagged by the instrument. Values above the measuring range are reported as > 1000 U/mL.

**Dilution**

Samples with CMV IgG concentrations above the measuring range must be prediluted with Diluent Universal prior to testing with the Elecsys CMV IgG Avidity assay. The recommended predilution is 1:20 (manually). The concentration of the prediluted sample must be ≥ 15 U/mL. This manual predilution must not be considered for avidity (Avi%) calculation as the manually prediluted sample is used for both measurements (reference measurement and DiICMVAv treated measurement).

Note: Antibodies to CMV are heterogeneous. This may lead to non-linear dilution behavior.

**Specific performance data**

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

**Precision**

Precision was determined using Elecsys reagents, human samples and controls in a protocol (EP5-A2) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days (n = 84); repeatability n = 21. The following results were obtained:

# Elecsys CMV IgG Avidity



cobas e 411 analyzer						
Sample	Repeatability			Intermediate precision		
	Mean Avi%	SD Avi%	CV %	Mean Avi%	SD Avi%	CV %
Human serum 1	9.8	0.1	1.0	9.8	0.2	2.3
Human serum 2	50.0	0.8	1.5	50.0	1.0	2.0
Human serum 3	81.1	1.4	1.7	81.1	1.8	2.2
PC <sup>b)</sup> CMV IgG Avidity 1	28.5	0.6	1.9	28.5	0.9	3.1
PC CMV IgG Avidity 2	78.1	1.0	1.3	78.1	1.7	2.2

b) PC = PreciControl

MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers						
Sample	Repeatability			Intermediate precision		
	Mean Avi%	SD Avi%	CV %	Mean Avi%	SD Avi%	CV %
Human serum 1	9.4	0.1	1.2	9.4	0.3	3.4
Human serum 2	53.1	0.8	1.5	53.1	0.9	1.6
Human serum 3	85.0	1.1	1.3	85.0	1.5	1.7
PC CMV IgG Avidity 1	29.6	1.0	3.4	29.6	1.1	3.8
PC CMV IgG Avidity 2	79.5	1.1	1.4	79.5	1.2	1.5

## Analytical specificity

439 potentially cross reacting samples were tested with the Elecsys CMV IgG assay (which equals to the Elecsys CMV IgG Avidity reference measurement) and a comparison CMV IgG assay comprising the following specimens:

- containing antibodies against HBV\*\*, HAV, HCV\*, HIV, HTLV, EBV\*\*, HSV\*, VZV\*\*, Parvo B19\*\*\*, Rubella, Treponema pallidum\*\*, Toxoplasma gondii\*\*
- containing autoantibodies\*\*\* (ANA, anti-tissue, RF)

An overall agreement of 96.6 % (422/437) was found in these specimens with the Elecsys CMV IgG Avidity reference measurement and the comparison test. 110 samples were found concordantly negative and 312 samples were found positive. 2 samples were found indeterminate either with the Elecsys CMV IgG assay or the comparison test.

\* HSV, HCV: 2 discordant samples were found in each group.

\*\* HBV, EBV, VZV, Treponema pallidum, Toxoplasma gondii: 1 discordant sample was found in each group.

\*\*\* Parvo B19, autoantibodies: 3 discordant samples were found in each group.

## Sensitivity

**Sensitivity (concordance of low avidity results with primary infections):**

The sensitivity of the CMV IgG avidity assay is defined as the percentage of samples of CMV primary infections (characterized by reference laboratories) detected to contain low avidity CMV IgG antibodies.

Overall 183 single and sequential samples collected by reference laboratories and characterized (based on diagnostic testing and if available, clinical indications) to be from primary CMV infections were investigated. 31 samples showed a gray-zone result and were excluded from calculation.

Sample type	Sensitivity (%)	Lower 95 % confidence limit (%)	Upper 95 % confidence limit (%)
Diagnostic	96.1 (74/77)	89.0	99.2
Pregnant women	93.4 (99/106)	86.9	97.3

Sample type	Sensitivity (%)	Lower 95 % confidence limit (%)	Upper 95 % confidence limit (%)
Total	94.5 (173/183)	90.2	97.4

**Relative sensitivity (concordance of low avidity results to a commercial CMV IgG avidity assay):**

Single specimens from randomly selected blood donor samples with CMV IgG seroconversion from the previous to the actual donation and characterized to contain CMV IgG low avidity antibodies with a commercial CMV IgG avidity assays were investigated. In 23 samples out of 26 samples low avidity CMV IgG antibodies were detected. 1 sample showed a gray-zone result.

## Specificity

**Specificity (concordance of high avidity results with late infections):**

The specificity of the CMV IgG avidity assay is defined as the percentage of samples of CMV late infections (characterized by reference laboratories) detected to contain high avidity CMV IgG antibodies.

A total of 95 single samples collected by a reference laboratory and characterized (based on diagnostic testing) to be from late CMV infections were investigated.

12 samples showed a gray-zone result and were excluded from calculation.

Sample type	Specificity (%)	Lower 95 % confidence limit (%)	Upper 95 % confidence limit (%)
Diagnostic	90.9 (40/44)	78.3	97.5
Pregnant women	100 (51/51)	93.0	100
Total	95.8 (91/95)	89.6	98.8

**Relative specificity (concordance of high avidity results in CMV IgG reactive, CMV IgM non-reactive samples indicating the absence of a primary infection):**

A total of 375 samples from blood donor testing and pregnancy screening (calculated from CMV IgG reactive, CMV IgM non-reactive samples with a concordant high avidity results in a comparison method indicating the absence of a primary infection) were investigated. 24 samples showed a gray-zone result and were excluded from calculation.

Sample type	Relative specificity (%)	Lower 95 % confidence limit (%)	Upper 95 % confidence limit (%)
Blood donors	97.9 (137/140)	93.9	99.6
Pregnant women	100 (235/235)	98.4	100
Total	99.2 (372/375)	97.7	99.8

## Distribution of avidity


The ability to discriminate between acute and late CMV infection is shown with 422 single and sequential samples collected by reference laboratories and classified into one of the following categories:

- Category A: < 90 days after presumed onset of infection or date of first bleed (single and sequential samples of patients initially suffering from a CMV primary infection); n = 225 samples

# Elecsys CMV IgG Avidity

- Category B: 90-180 days after presumed onset of infection or date of first bleed (single and sequential samples of patients initially suffering from a CMV primary infection); n = 66 samples
- Category C: > 180 days after presumed onset of infection or date of first bleed (single and sequential samples of patients initially suffering from a CMV primary infection); n = 131 samples

The exact distribution of low avidity, gray-zone and high avidity results is given in the following diagram:



## References

- Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. *Rev Med Virol* 2010;20:202-213.
- Johnson J, Anderson B, Pass RF. Prevention of maternal and congenital cytomegalovirus infection. *Clin Obstet Gynecol* 2012;55:521-530.
- Yinon Y, Farine D, Yudin MH. Screening, diagnosis, and management of cytomegalovirus infection in pregnancy. *Obstet Gynecol Surv* 2010;65:736-743.
- Buonsenso D, Serranti D, Gargiullo L, et al. Congenital cytomegalovirus infection: current strategies and future perspectives. *Eur Rev Med Pharmacol Sci* 2012;16:919-935.
- Coll O, Benoit G, Ville Y, et al. WAPM Perinatal Infections Working Group. Guidelines on CMV congenital infection. *J Perinat Med* 2009;37:433-445.
- Joseph S, Beliveau C, Muecke C, et al. Cytomegalovirus as an occupational risk in daycare educators. *Paediatr Child Health* 2006;11:401-407.
- Lazzarotto T, Guerra B, Lanari M, et al. New advances in the diagnosis of congenital cytomegalovirus infection. *J Clin Virol* 2008;41:192-197.
- Lombardi G, Garofoli F, Stronati M. Congenital cytomegalovirus infection: treatment, sequelae and follow-up. *J Matern Fetal Neonatal Med* 2010;23 Suppl 3:45-48
- Elliott SP. Congenital cytomegalovirus infection: an overview. *Infect Disord Drug Targets* 2011;11:432-436.
- Lazzarotto T, Guerra B, Gabrielli L, et al. Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. *Clin Microbiol Infect* 2011;17:1285-1293.
- Plosa EJ, Esbenshade JC, Fuller MP, et al. Cytomegalovirus infection. *Pediatr Rev* 2012;33:156-163.
- Ross SA, Novak Z, Pati S, et al. Overview of the diagnosis of cytomegalovirus infection. *Infect Disord Drug Targets* 2011;11:466-474.
- Occupational Safety and Health Standards: Bloodborne pathogens. (29 CFR Part 1910.1030). Fed. Register.
- Directive 2000/54/EC of the European Parliament and Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

## Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see <https://usdiagnostics.roche.com> for definition of symbols used):

CONTENT	Contents of kit
SYSTEM	Analyzers/Instruments on which reagents can be used
REAGENT	Reagent
CALIBRATOR	Calibrator
→	Volume after reconstitution or mixing
GTIN	Global Trade Item Number

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2017, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim  
[www.roche.com](http://www.roche.com)

